Bausch’s Salix Agrees to License NASH Treatment Compound from U. Cal.

Salix Pharmaceuticals (“Salix”), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, and a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), announced its affiliate has entered into a license agreement with the University of California (“UCLA”) via UCLA’s Technology Development Groupfor certain intellectual property relating to an investigational compound targeting the pituitary adenylate cyclase receptor 1 (PAC1) in non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and various other gastrointestinal and liver diseases.

“With our in-depth knowledge and experience in the treatment of gastrointestinal and liver diseases, we believe we can make a difference in bringing forward potential treatments for NAFLD and NASH, two areas of significant unmet medical need today,” said Mark McKenna, president, Salix Pharmaceuticals. “This novel compound is representative of the caliber of products in our portfolio, as we remain committed to researching gastrointestinal and liver disease treatments needed today and in the future.”

https://www.marketscreener.com/BAUSCH-HEALTH-COMPANIES-I-44965076/news/Salix-Enters-Into-License-Agreement-With-The-University-Of-California-To-Develop-And-Commercialize-N-28392960/